IDH1 and acute myeloid leukemia: A trial examining IDHi in combination with chemotherapy for newly diagnosed AML or myelodysplastic syndrome EB2 with an IDH1 or IDH2 mutation is currently ongoing (https://clinicaltrials.gov/, NCT03839771).